“Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials
Cephalalgia · 2023-04 · 43 (4)
DOI: 10.1177/03331024231161261 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cephalalgia, online erschienen am 16.03.2023. Verfasst von Thanin Asawavichienjinda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thai…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Migraine Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
A new migraine prevention, CGRP monoclonal antibodies (mAbs), is injectable on a monthly or quarterly basis. In clinical practice, some patients reported that drug effectiveness does not last until the upcoming scheduled injection, a so-called “wearing-off” effect. We aimed to evaluate the wearing-off effect of the CGRP mAbs for migraine prevention in patients with different monthly migraine days.
Methods
We conducted a literature search for studies that reported migraine frequency after CGRP monoclonal antibody administration from MEDLINE, SCOPUS, Web of Science, and Cochrane Database from inception through February 2022. A meta-analysis, random-effects model was applied to assess the difference in migraine frequency between early and later weeks after medication to assess the presence of a wearing-off effect. Risk ratio was calculated to report the pooled treatment effect.
Results
Four studies were entered for the analysis, comprising 2409 patients in randomized controlled trials. There was no association between CGRP mAbs and wearing-off effect in patients with galcanezumab with a pooled risk ratio of 1.29 (95% CI 0.73 to 2.28) compared to placebo group. However, there was an association between galcanezumab and wearing-off effect in patients with chronic migraine with a pooled risk ratio of 1.91 (95% CI 1.11 to 3.28) compared to placebo group.
Conclusion
In this meta-analysis, there was a wearing-off efficacy of galcanezumab but only in a small percentage of patients with chronic migraine in randomized controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
ORCID-Profile: Thanin Asawavichienjinda, Seelwan Sathitratanacheewin
Zitieren
APA
Asawavichienjinda, T., Sathitratanacheewin, S., & Chokesuwattanaskul, R. (2023). “Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia, 43(4). https://doi.org/10.1177/03331024231161261
Vancouver
Asawavichienjinda T, Sathitratanacheewin S, Chokesuwattanaskul R. “Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia. 2023;43(4). doi:10.1177/03331024231161261
BibTeX
@article{Asawavichienjinda2023,
author = {Asawavichienjinda, Thanin and Sathitratanacheewin, Seelwan and Chokesuwattanaskul, Ronpichai},
title = {“Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials},
journal = {Cephalalgia},
year = {2023},
volume = {43},
number = {4},
doi = {10.1177/03331024231161261}
}
EUVIMED